Stay updated with breaking news from Anders Ullman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sobi ® will present new data at the hybrid EHA (European Haematology Association) congress taking place in Vienna from 9-17 June 2022, highlighting the company's commitment in rare haematological diseases
Efanesoctocog alfa significantly and meaningfully reduces annualised bleeding rates in haemophilia A patients.
Investegate announcements from Sanofi - Aventis Groupe, Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection)...
Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection)...